Posted on 02-Mar-2017
1. Summary of the notifications
Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received one transparency notification dated 27 February 2017, from Wellington Management Group LLP (having its registered offices at 280 Congress Street, Boston, MA 02110, USA) and one transparency notification dated 28 February 2017, from BlackRock, Inc. (having its registered offices at 55 East 52nd Street, New York, NY, 10055, USA).
Wellington Management Group LLP has notified that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV has increased and has crossed the 3% threshold on 23 February 2017.
BlackRock, Inc. has notified that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV has increased and has crossed the 3% threshold on 27 February 2017.
On 23 February 2017, Wellington Management Group LLP (taking into account the holding of its affiliates) owned 5 909 710 UCB shares with voting rights (versus 5 800 898 UCB shares in its previous notification dated 22 February 2017), representing 3.04% of the total number of shares issued by the company (194 505 658) (versus 2.98% in its notification dated 22 February 2017).
On 27 February 2017, BlackRock, Inc. (taking into account the holding of its affiliates) owned 5 838 933 UCB shares with voting rights (versus 5 654 855 UCB shares in its previous notification dated 23 February 2017), representing 3.00% of the total number of shares issued by the company (versus 2.91% in its notification dated 23 February 2017).
2. Content of the notifications
The transparency notification of Wellington Management Group LLP dated 27 February 2017 included the following information:





The information mentioned hereafter was identical in both notifications:
3. Further information
This press release and the detailed transparency notifications are available on UCB SA/NV’s website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.
Investor Relations
Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com
Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases
of the immune system or of the central nervous system. With more than 7 700 people in approximately 40 countries, the company generated revenue of € 4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news TOTAL (A & B) # of voting rights % of voting rights CALCULATE 5.981.866 3,08%